ONCOTYPE DX® TESTS

Every cancer is unique and affects each diagnosed person differently based on the individual biology of his or her disease. To address this diversity and make cancer care smarter at every stage, our Oncotype IQ® genomic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient's tumour. This additional genomic insight helps clinicians optimise treatment decisions for breast, colon, and prostate cancers by answering questions such as:

  • Do I need chemotherapy?
  • Do I have an aggressive form of cancer?
  • Do I need surgery?
  • Will I need additional treatment after surgery?
The Oncotype DX tests have been used to guide treatment decisions for more than 1 million cancer patients worldwide.

VISIT ONCOTYPEIQ.COM UK ORDERING PORTAL

teamwork

"With millions of cancer patients around the world, it is critical to be able to individualise care. Oncotype DX tests have paved the way for precision medicine by providing personalised information based on the unique biology of every cancer, and by enabling confident, individualised treatment decisions. Genomic testing has become a mainstream component of cancer care, and patients are seeing the benefits through improved outcomes."

Harold A. Burstein, M.D., Ph.D.Medical Oncologist at the Dana-Farber Cancer Institute

MAKING CANCER CARE SMARTER
ONCOTYPE DX® TESTS

ONCOTYPE DX TEST FOR BREAST CANCER

Learn more about the Oncotype DX test for early-stage breast cancer

LEARN MORE

ONCOTYPE DX TEST FOR PROSTATE CANCER

Learn more about the Oncotype DX test for early-stage prostate cancer

LEARN MORE

ONCOTYPE DX TEST FOR COLON CANCER

Learn more about the Oncotype DX test for colon cancer

LEARN MORE

You are now leaving this site.

Any third-party link you select from this site may take you to an Exact Sciences website intended for US audiences or a website that is not affiliated with Exact Sciences.

I agree